Home - Healixia

REGISTER NOW for our Annual Conference 2023, we are looking forward to welcoming you!

___________________________________________________________

Healixia is the Belgian community of all professionals active along the life cycle of medicines, medical devices, in vitro diagnostics & other health related products. Members are active in research & development (including pre-clinical, early clinical and later phases), medical affairs, safety, regulatory affairs and market access in industry, academia, investigator sites, authorities, regulatory bodies or in consultancy.

Become a member

Healixia provides education, training and networking opportunities within and across each of the 4 domains it represents.

Healixia events

27 April '23

Healixia Annual Conference 2023
Grimbergen

There are 122 places available. Cross-domains

REGISTER NOW for our ANNUAL CONFERENCE 2023!

Read more
23 May '23

Healixia Conference: Deep Dive into BeNeLuxA
Grimbergen

There are 90 places available. Cross-domains, Medical Affairs

Come and benchmark your current knowledge with actual insights and developments and receive practice advice, gain insight and discuss with peers about the challenges and opportunities.

Read more
08 June '23

Healixia General Assembly 2023 (members only)
Grimbergen
Cross-domains

On the agenda:

Approval activity report and financials Healixia 2022

Approval action plan and budget Healixia 2023

Mandates Board Members: ‘discharge’

Program:

16h45: Registration

17h00: General Assembly
Read more

Show all meetings

News

March 28, 2023
Reform of medicines reimbursement procedures by Riziv-Inami

We werken aan een vernieuwend geneesmiddelenbeleid om een duurzame en toekomstbestendige toegankelijkheid van waardevolle farmaceutische specialiteiten voor patiënten in België te garanderen. Dit omvat een optimalisatie van de verschillende schakels voor alle betrokken stakeholders in het geneesmiddelenbeleid.

Depuis 2022, nous sommes en train d’élaborer une politique innovante en matière de médicaments, dans le but de garantir aux patients un accès durable à des spécialités pharmaceutiques de qualité en Belgique. Il s‘agit notamment d’optimiser les différents « maillons » pour tous les intervenants impliqués dans la politique des médicaments.

Source: Riziv-Inami

Read more
March 23, 2023
Extension of transition period for the European Regulations for medical devices and for in-vitro diagnostics

Vandaag besliste de Raad van Europa en het Europese Parlement om een langere overgangsperiode te voorzien om aangemelde instanties (notified bodies) en fabrikanten meer tijd te geven om medische hulpmiddelen te certificeren en zo het risico van tekorten te beperken zodat patiënten in nood toegang blijven houden tot medische hulpmiddelen.

Aujourd'hui, le Conseil de l'Europe et le Parlement européen ont décidé de prévoir une période de transition plus longue afin de donner aux organismes notifiés (notified bodies) et aux fabricants plus de temps pour certifier les dispositifs médicaux, réduisant ainsi le risque de pénurie afin que les patients qui en ont besoin continuent d'avoir accès aux dispositifs médicaux.

Source: FAMHP

Read more
March 23, 2023
New system for financing the surveillance of the medical devices market

A new system for financing the surveillance of the medical devices market applies from 2023. This system aims to make fees fairer between the different stakeholders in the sector, as each one must pay a fee that is consistent with its turnover and with the level of risk involved in its activity and in the workload it represents for the FAMHP.

Source: FAMHP

Read more